Virtus ETF Advisers’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-3,458
| Closed | -$65.1K | – | 526 |
|
|
2024
Q4 | $65.1K | Sell |
3,458
-2,054
| -37% | -$38.7K | 0.03% | 420 |
|
|
2024
Q3 | $124K | Buy |
5,512
+101
| +2% | +$2.27K | 0.06% | 348 |
|
|
2024
Q2 | $113K | Sell |
5,411
-4,282
| -44% | -$89.4K | 0.06% | 329 |
|
|
2024
Q1 | $142K | Sell |
9,693
-663
| -6% | -$9.75K | 0.08% | 335 |
|
|
2023
Q4 | $107K | Buy |
10,356
+1,345
| +15% | +$13.9K | 0.07% | 334 |
|
|
2023
Q3 | $70.8K | Sell |
9,011
-901
| -9% | -$7.08K | 0.04% | 383 |
|
|
2023
Q2 | $99K | Buy |
9,912
+1,731
| +21% | +$17.3K | 0.06% | 386 |
|
|
2023
Q1 | $72.6K | Sell |
8,181
-3,151
| -28% | -$28K | 0.04% | 399 |
|
|
2022
Q4 | $124K | Buy |
11,332
+519
| +5% | +$5.7K | 0.07% | 409 |
|
|
2022
Q3 | $141K | Buy |
10,813
+78
| +0.7% | +$1.02K | 0.06% | 363 |
|
|
2022
Q2 | $136K | Buy |
10,735
+5,059
| +89% | +$64.1K | 0.05% | 336 |
|
|
2022
Q1 | $80K | Sell |
5,676
-334
| -6% | -$4.71K | 0.04% | 337 |
|
|
2021
Q4 | $174K | Sell |
6,010
-1,183
| -16% | -$34.3K | 0.07% | 266 |
|
|
2021
Q3 | $216K | Sell |
7,193
-377
| -5% | -$11.3K | 0.1% | 249 |
|
|
2021
Q2 | $201K | Buy |
+7,570
| New | +$201K | 0.08% | 342 |
|